A concise, up-to-date bio of the subject
Oura has postponed its planned Nasdaq flotation due to uncertainty in the IPO market, while noting strong demand and continued revenue growth. The company remains profitable with growing subscription revenue and expanded health-tracking features, and says the delay is a strategic choice, not a signal of deteriorating fundamentals.
A class-action-like suit claims Oura’s sleep tracking relies on AI estimates rather than physiological signals, arguing the ring cannot accurately determine sleep stages. The case cites a Nature study showing limited accuracy, while Oura defends its methodology and insists its data are scientifically grounded.